Therapeutic Drug Monitoring of Tigecycline in 67 Infected Patients and a Population Pharmacokinetics/Microbiological Evaluation of A. baumannii Study
Authors:
Open Access
- 16 June 2021
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Microbiology
- Vol. 12
Abstract
Background: The widespread use of antibiotics has led to the emergence of multidrug-resistant (MDR) bacteria such as multidrug-resistant Acinetobacter baumannii (AB). Tigecycline (TGC), as the first glycylcycline antibiotic approved by FDA, is a broad-spectrum antibiotic which remains highly effective to treat AB infections.Objective: To confirm the TGC treatment dosage and effectiveness to treat AB infections in the Chinese population by performing therapeutic drug monitoring (TDM).Methods: This study was performed from October 2018 through March 2019 at the PLA General Hospital. A high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) method was validated and employed to determine the plasma concentrations of TGC in patients with infectious diseases. The minimum inhibitory concentration (MIC) of TGC to clinically isolated AB was determined by broth microdilution method, agar dilution method, and disk diffusion method. Moreover, a model of population pharmacokinetics/pharmacodynamics (PPK/PD) was constructed.Results: A total of 186 plasma samples from 67 patients were detected by the validated HPLC-MS/MS method. The MIC values determined by the broth microdilution method were more sensitive and accurate than the other two methods. The microbial and clinical PK/PD breakpoints were reached when the maintenance dose of TGC was 100 mg.Conclusion: Our study established a validated HPLC-MS/MS method to monitor the plasma concentrations of TGC. In view of the MIC range to AB isolates in our hospital and the PPK/PD modeling results, we recommend a relatively high dose of 100 mg q12h regimen to achieve the optimal clinical efficacy and antimicrobial response.Keywords
This publication has 19 references indexed in Scilit:
- Development and validation of an LC‐MS/MS method for the determination of tigecycline in human plasma and cerebrospinal fluid and its application to a pharmacokinetic studyBiomedical Chromatography, 2016
- Comparative assessment of antimicrobial susceptibility testing for tigecycline and colistin against Acinetobacter baumannii clinical isolates, including multidrug-resistant isolatesInternational Journal of Antimicrobial Agents, 2014
- High dose tigecycline in critically ill patients with severe infections due to multidrug-resistant bacteriaCritical Care, 2014
- Therapeutic drug monitoring for tomorrowEuropean Journal of Clinical Pharmacology, 2013
- Randomized Phase 2 Trial To Evaluate the Clinical Efficacy of Two High-Dosage Tigecycline Regimens versus Imipenem-Cilastatin for Treatment of Hospital-Acquired PneumoniaAntimicrobial Agents and Chemotherapy, 2013
- Pharmacological and Patient-Specific Response Determinants in Patients with Hospital-Acquired Pneumonia Treated with TigecyclineAntimicrobial Agents and Chemotherapy, 2012
- [Comparison of disc diffusion, E-test, and broth microdilution methods for the determination of resistance to colistin, polymyxin B, and tigecycline in multi-resistant Acinetobacter baumannii isolates].2010
- Population Pharmacokinetics of Tigecycline in Patients with Complicated Intra-Abdominal or Skin and Skin Structure InfectionsAntimicrobial Agents and Chemotherapy, 2006
- Serum, tissue and body fluid concentrations of tigecycline after a single 100 mg doseJournal of Antimicrobial Chemotherapy, 2006
- In-vitro susceptibility of anaerobic bacteria to gar-936, a new glycylcyclineClinical Microbiology and Infection, 2000